Inspire Medical Systems Board Authorizes $200M Share Repurchase Program

Inspire Medical Systems has announced a $200 million share repurchase program authorized by its Board of Directors. The company is focused on developing and commercializing minimally invasive solutions for obstructive sleep apnea. The repurchase program aims to support the full U.S. launch of Inspire V, the company's next-generation neurostimulation system.

Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company specializing in minimally invasive solutions for obstructive sleep apnea (OSA), has announced a $200 million share repurchase program authorized by its Board of Directors. The program, which will run until August 7, 2027, aims to support the company's significant growth initiatives, including the recent full U.S. launch of Inspire V, its next-generation neurostimulation system [1].

The repurchase program, which allows the company to buy back its common stock, reflects Inspire's strong financial position. CEO Tim Herbert emphasized that the company's robust cash flow and balance sheet enable it to return capital to shareholders while continuing to invest in growth and expansion. The repurchase program provides flexibility in terms of timing, method, and amount of shares to be repurchased, with no obligation to complete the full program [2].

Inspire's decision to authorize this share repurchase program is seen as a vote of confidence in the company's future prospects. The company maintains that its stock is undervalued relative to its growth potential, making share repurchases an attractive investment opportunity. The repurchase program is expected to represent a meaningful percentage of the company's market capitalization, signaling a strategic capital allocation strategy [2].

The announcement comes amidst the company's largest product launch ever, the Inspire V neurostimulation system. This system represents a significant advancement in treating moderate to severe OSA, with Inspire's proprietary technology being the first and only FDA, EU MDR, and PDMA-approved neurostimulation technology of its kind [1].

Inspire's minimal penetration into its addressable sleep apnea market further underscores the substantial growth potential of the company. The dual approach of capital return and continued investment in growth initiatives highlights Inspire's ability to manage its financial resources effectively while pursuing aggressive expansion plans.

References:
[1] https://www.morningstar.com/news/globe-newswire/9509579/inspire-medical-systems-inc-board-authorizes-share-repurchase-program
[2] https://www.stocktitan.net/news/INSP/inspire-medical-systems-inc-board-authorizes-share-repurchase-cbea6ftzqrpb.html